

„LABORATORY IMMUNETECHNIQUES IN MOLECULAR BIOLOGY RESEARCH” methodical course

9-13st December 2019

**Introduction. Immunisation. Polyclonal and
monoclonal antibody production, purification
and labelling for practical use.**

Course code: OPEL_B-139_NEP1

The competition of course equals to 6 ECTS credits.



Immunological techniques

MICROANALITIKAL METHODS

- **immunoserology**
- **immunohistochemistry**

FUNCTIONAL TESTS

- ***in vitro* methods (tissue cultures)**
- ***in vivo* methods**



NUCLEIC ACID TECHNIQUES

Immunoserology

- **Methods based on immunoprecipitation**
 - Radial immunodiffusion (Mancini)
 - Radial double immunodiffusion (Ouchterlony)
 - IELFO
 - Nephelometria
- **Methods based on agglutination**
 - Coomb's test (direct, indirect)
 - Latex agglutination
 - Quick tests
- **Micro immunoassais**
 - RIA, ELISA, FIA, RIF





Structure of immunoglobulin G




Antibody affinity maturation


Pini et al. (1998) J. Biol. Chem. *273*, 21769-21776



1st library



2nd library



3rd library

Factors influencing the antibody production

- **MHC haplotype of the recipient**
- **Nature and origin of the antigen**
- **Dose of the antigen**
- **Mode of the administration**
- **Adjuvants**
- **Kinetics of the immunisation**

Production of the antibodies

- **Policlonal antibodies - antisera**
 - immunisation
 - antibody purification
 - labeling for practical applications
- **Hybridomas and monoclonal antibodies**
 - antibody design and production
 - large scale fermentation of the best clones
 - labeling for practical applications

Animals for immunisation








FIG. 4



The production of an antiserum: bleeding an immunized horse from the jugular vein.

Kinetics of immunoglobulin production





Radial immunodiffusion (Mancini technique)



Double immunodiffusion (Ouchterlony technique)



DIRECT COOMB'S TEST



Example: The baby's sample is positive for the presence of the mother's Ab on the surface of RBCs in erythroblastosis fetalis


Agglutination

INDIRECT COOMB'S TEST




Example: A mother who is Rh⁻ can have prenatal testing to determine the presence of nonagglutinating Ab in her bloodstream that will attack the fetus's RBCs if the father is Rh⁺

Agglutination




Immunelectrophoresis




Nephelometric turbidity

Enzyme Linked Immunosorbent Assay (ELISA)




ELISA

ELISA testing of western flower thrips for INSV
(red color is a positive result)




RIA Diagram



RIA



Quick test






Immunohisto/cytochemistry

- **Light microscopic methods** (autoradiography, enzyme-immunocytochemistry)
 - Immunohistochemical image analysis
- **Fluorescent microscopic methods**
 - Conventional immunofluorescence
 - Laser scanning (confocal) microscopy
- **Flow cytometry**
 - Cell surface and intracytoplasmic labelling
 - Microbead technique (MMA)




Immunohistochemical applications



Autoradiography




**Immuno-
fluorescence**




**Enzyme
immunohisto-
chemistry**

Flow cytometry



Flow Cytometric Analysis of Phospho-p44/42 (ERK1/2), CD3, and CD4





Multicolor analysis of human PBMCs stained with anti-CD3, anti-CD4, and anti-phospho-p44/42 (T202/Y204) Alexa Fluor® 647. PBMCs were depleted of adherent cells and stimulated by CD3/CD28 crosslinking (15 min at 4 °C) or PMA/ionomycin treatment (500 ng/ml for 30 min at 37 °C). Following treatment, cells were washed, fixed, permeabilized, and stained with all three antibodies simultaneously. Cells were analyzed on a BD FACSCalibur™ flow cytometer. The results show that phospho-p44/42 (T202/Y204) was upregulated in only the CD3+/CD4+ double positive cells.

Data courtesy of Omar Perez, PhD - Nolan Laboratory, Stanford University

In vitro functional tests


■ **Short term cultures**

- analysis of cell migration
- phagocytosis tests (sheep RBC, lisosyme, NBT)
- activity analysis
(mixed lymphocyte culture, cytotoxicity)




■ **Continous cell cultures**

- autoantibody analysis
- cytotoxicity tests



***In vivo* functional tests**

- Immunotoxicity tests
- Skin window test
- Passive cutan anaphylaxis (PCA)



Characteristics of polyclonal antibodies

- Blood serum (variable idiotypes, different isotypes, mixture of antibodies with different affinity)
- Characterised by avidity
- Standard in bench

Immunoglobulin purification

Salt precipitation $(\text{NH}_4)_2\text{SO}_4$


Liquid chromatography

Affinity chromatography (Fc end, antigen)




Affinity purification

Protein A




Protein G

immunoglobulin binding domain of protein G




Hybridomas and monoclonal antibodies



César Milstein és Georg Köhler

Nobel prize, 1984: *"for theories concerning the specificity in development and control of the immune system and the discovery of the principle for production of monoclonal antibodies"*


Monoclonal Antibody Production



Characteristics of monoclonal antibodies

- Genetically engineered antibodies
- Specific in single epitope
- Uniform antibody molecules
- Characterised by chemical affinity
- Standard by the cell line

Somatic cell hybridisation and selection



mouse myeloma




HGPRT⁻

PEG





HGPRT⁺

mouse B cell
(both die in HAT)




hybrid myeloma
(survives in HAT,
produces myeloma Ab
and B cell Ab)







Murine




Chimaeric




Humanised




Human







Intact IgG



Monovalent fragments



Diabodies
(~60 kDa)





Triabodies (~90 kDa)



Fab conjugates: dimers and trimers



Minibody



Tetrabodies (~120 kDa)



Hybridoma culturing



First monoclonal antibodies for therapeutic use

Generic name	Trade name	Sponsor company	Type	Approval date
Muromonab-CD3	Orthoclone	Ortho Biotech	Murine	1986
Abciximab	ReoPro	Centocor	Chimeric	1994
Rituximab	Rituxan	Genentech	Chimeric	1997
Daclizumab	Zenapax	Hoffman-La Roche	Humanized	1997
Basiliximab	Simulect	Novartis	Chimeric	1998
Palivizumab	Synagis	MedImmune	Humanized	1998
Infliximab	Remicade	Centocor	Chimeric	1998
Trastuzumab	Herceptin	Genentech	Humanized	1998
Gemtuzumab ozogamicin	Mylotarg	Wyeth-Ayerst	Humanized	2000
Alemtuzumab	Campath	Millennium/ILEX	Humanized	2001

Licences are expired in 2010 and 2011. Number of therapeutic monoclonal antibodies in the market is closed to 2000 including biosimilars.

November 10, 2017, **68** new monoclonal antibody products have been approved in the US or in the EU for the treatment of a variety of diseases. At the current approval rate of ~70 new original monoclonal antibody products will be on the market by 2020, and combined world-wide sales will be nearly \$125 billion.





Fermentation in industrial scale


















New production greenhouse facilities are also available to through a collaboration with the University of Arkansas at Fayetteville. These plant growth facilities will support cGMP compliant growth of **transgenic plants for the expression of monoclonal antibodies in plants.**

Immunotoxin therapy






HER-2/neu



Confocal microscope image showing the internalisation of an anti-CD7 sapotin immunotoxin by human T-leukaemia cells into intracellular vesicles (green stain) in relation to the trans-golgi region (red stain)




Gemtuzumab Ozogamicin

Proposed indication:

"For the Treatment of CD 33 positive acute myeloid leukemia in relapse"

Immunotoxin therapy of „Hairy Cell” leukaemia





Nomenclature of therapeutic mononclonal antibodies

Prefix (variable) – **Target** – **Origin** – **mab**



(E.g. *anti-CD20* *Ri tu xi mab*)

TARGET		ORIGIN	
b(a)	bacterium	-a-	rat
c(i)	circulatory system	-e-	hamster
f(u)	fungus	-i-	primat
k(i)	interleukin	-o-	mouse
l(i)	immune system	-u-	human
n(e)	nervous system	-xi-	chimeric
s(o)	bone	-zu-	humanized
tox(a)	toxin	-xizu-	chimeric/humanized hybrid
t(u)	tumor	-axo-	rat/mouse hybrid
v(i)	virus		

Antibody labelling for laboratory use



Amplification techniques





Fluorescent labelling

Excitation Wavelength	Fluorochromes/Dyes	Standard Filter	Optional Filter
488 nm	FITC, BB515, Alexa Fluor® 488, CFSE	533/30	–
	GFP	533/30	510/15
	JC-1, Fluo-4 AM, SYBR® Green	533/30	–
	YFP	533/30	540/20
	PE, JC-1, BD™ MitoStatus TMRE	585/40	–
	OFP	585/40	565/20
	Propidium Iodide	585/40, 670 LP	610/20
	BD Horizon™ PE-CF594	670 LP	610/20
	RFP, mCherry, dsRed	670 LP	610/20
	PerCP, PE-Cy™5	670 LP	–
	PerCP-Cy™5.5	670 LP	–
	7-AAD	670 LP	–
	PE-Cy™7	670 LP	780/60
640 nm	APC, BD™ MitoStatus Red, Alexa Fluor® 647	675/25	–
	APC-H7, APC-Cy7	670 LP	780/60

Combination of labelling methods



Enzymatic	<i>Fluorescent Dyes</i>			Haptens
	Near UV	Visible	Near IR	
Alkaline Phosphatase	ATTO 425	ATTO 488	Allophycocyanin	Biotin
		ATTO 532	Cy5™	
Beta Galactosidase	ATTO 488	ATTO 550	ATTO 647	Biomagnetic Particles
	Cy2™	Cy3™	DyLight™ 649	
		Cy5™	ATTO 655	Streptavidin
	DyLight™ 405	DyLight™ 488	Cy5.5™	
Horseradish Peroxidase		DyLight™ 549	DyLight™ 680	Protein A/G
	DyLight™ 488	Texas Red	DyLight™ 800	

Gold labeling



Size comparison:
(A) conventional BSA-stabilized
colloidal gold-IgG probe, vs.
(B) Nanogold-Fab' probe

Sequential Gold and Fluorescent Labeling



See the difference...

1.4 nm
Nanogold®

*The superior
gold probe.*



vs.
Colloidal Gold

10 nm